Keytruda (pembrolizumab)

pCPA File Number: 21928

Negotiation Status:

Concluded with an LOI

Indication(s):

in combination with Lenvima, for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic RCC

Sponsor/Manufacturer:

Merck Canada Inc.

CADTH Project Number:

PC0268

pCPA Engagement Letter Issued:

2022-10-21

Negotiation Process Concluded:

2023-05-12